In what is becoming a trend among anti-amyloid therapies for Alzheimer’s disease, bapineuzumab appeared to clear amyloid plaques from the brains of Alzheimer’s patients even though it provided no clinical benefits in early trials, researchers reported.  In a subanalysis of two phase III bapineuzumab trials, patients on the drug had a reduction in amyloid plaques on PET imaging compared with those on placebo, Enchi Liu, PhD, of Johnson & Johnson, reported online in Neurology. {read more here}